Encompass Health is projected to post Q3 2026 revenue of $1.60 billion and EPS of $1.37, while the stock currently trades at $124.09 against a consensus analyst target of $148.17.
Investors are primarily focused on same-store discharge growth, which serves as a critical barometer for organic demand in the inpatient rehabilitation segment.
Recent performance has been bolstered by the opening of new hospitals in Maine and Texas, part of a broader strategy to add 150-200 beds annually. Analysts are also watching for margin stability as labor costs continue to normalize across the healthcare services sector.